Reveromycin A

Reveromycin A

$325.00 - 0.25 mg

$1,140.00 - 1 mg

All prices in Australian dollars

Molecular Formula
Molecular Weight
>95% by HPLC
Long Term Storage
Soluble in ethanol, methanol, DMF or DMSO. Poor water solubility.

Download Data Sheets

Application Notes

Reveromycin A, the dominant analogue of a complex of spiroketals isolated from a Streptomyces sp., is an inhibitor of the mitogenic activity of EGF. Reveromycin A is a G1 phase cell cycle inhibitor, selectively inhibiting isoleucyl-tRNA synthetase. Reveromycin A displays antiproliferative behaviour against human cell lines KB and K562, as well as potent antifungal activity. More recently it has been shown to induce apoptosis in osteoclasts thus inhibiting bone resorption.


  • Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Woo J.T. et al., Proc Natl Acad Sci USA. 2006, 103, 4729.
  • Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an antiosteoclastic activity. Muguruma H. et al., Clin Cancer Res. 2005, 11, 8822.
  • Identification of Saccharomyces cerevisiae isoleucyl-tRNA synthetase as a target of the G1-specific inhibitor Reveromycin A. Miyamoto Y., et al., J. Biol. Chem., 2002, 277, 28810.

Other Products